<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36145288</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Vemurafenib Inhibits Enterovirus A71 Genome Replication and Virus Assembly.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1067</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15091067</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) infection is a major cause of hand, foot, and mouth disease (HFMD), which may be occasionally associated with severe neurological complications. There is currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation, and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late-stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC<sub>50</sub>) at nanomolar concentrations. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Bodan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chik</LastName><ForeName>Kenn Ka-Heng</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jasper Fuk-Woo</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0001-6336-6657</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou 571199, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jian-Piao</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-4077-3852</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hehe</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Jessica Oi-Ling</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Zijiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Yin-Po</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Kaiming</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7310-6744</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Lilong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Cuiting</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Feifei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou 571199, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou 571199, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zi-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2855-9837</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Man-Lung</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shuofeng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7996-1119</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CID-HKU1-11, ZDKJ202003 etc.</GrantID><Agency>the Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, etc</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MAPK signaling pathway</Keyword><Keyword MajorTopicYN="N">RAF</Keyword><Keyword MajorTopicYN="N">VP0 cleavage</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">genome replication</Keyword><Keyword MajorTopicYN="N">vemurafenib</Keyword><Keyword MajorTopicYN="N">virus assembly</Keyword></KeywordList><CoiStatement>J.F.-W.C. received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declared no conflict of interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36145288</ArticleId><ArticleId IdType="pmc">PMC9500672</ArticleId><ArticleId IdType="doi">10.3390/ph15091067</ArticleId><ArticleId IdType="pii">ph15091067</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region. J. Biomed. Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J. Biomed. Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:391. doi: 10.1038/s41579-018-0022-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0022-3</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung M.L., Jia L., Yip C.C.Y., Chan J.F.W., Teng J.L.L., Chan K.H., Cai J.P., Zhang C., Zhang A.J., Wong W.M., et al. Human tryptophanyl-tRNA synthetase is an IFN-gamma-inducible entry factor for Enterovirus. J. Clin. Investig. 2018;128:5163&#x2013;5177. doi: 10.1172/JCI99411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99411</ArticleId><ArticleId IdType="pmc">PMC6205371</ArticleId><ArticleId IdType="pubmed">30153112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K.L., Yoder J.L., Carnegie M.S., Ashley R.E., Makhov A.M., Conway J.F., Hafenstein S. The enterovirus 71 A-particle forms a gateway to allow genome release: A cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9:e1003240. doi: 10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang M., Cheng A., Wen X., Ou X., Mao S., Gao Q., Sun D., Jia R., Yang Q., et al. Enterovirus Replication Organelles and Inhibitors of Their Formation. Front. Microbiol. 2020;11:1817. doi: 10.3389/fmicb.2020.01817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01817</ArticleId><ArticleId IdType="pmc">PMC7468505</ArticleId><ArticleId IdType="pubmed">32973693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Liu H., Qu M., Hou A., Zhou Y., Sun B., Cai L., Gao F., Su W., Jiang C. Determination of the cleavage site of enterovirus 71 VP0 and the effect of this cleavage on viral infectivity and assembly. Microb. Pathog. 2019;134:103568. doi: 10.1016/j.micpath.2019.103568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2019.103568</ArticleId><ArticleId IdType="pubmed">31195113</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M.F., Baltimore D. Morphogenesis of poliovirus: I. Association of the viral RNA with coat protein. J. Mol. Biol. 1968;33:369&#x2013;378. doi: 10.1016/0022-2836(68)90195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(68)90195-2</ArticleId><ArticleId IdType="pubmed">4302632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler-Bostock R., Mata C.P., Bingham R.J., Dykeman E.C., Meng B., Tuthill T.J., Rowlands D.J., Ranson N.A., Twarock R., Stockley P.G. Assembly of infectious enteroviruses depends on multiple, conserved genomic RNA-coat protein contacts. PLoS Pathog. 2020;16:e1009146. doi: 10.1371/journal.ppat.1009146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009146</ArticleId><ArticleId IdType="pmc">PMC7793301</ArticleId><ArticleId IdType="pubmed">33370422</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S., Fry E., Blakemore W., Abu-Ghazaleh R., Jackson T., King A., Lea S., Newman J., Stuart D. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: The structure of empty capsids of foot-and-mouth disease virus. J. Virol. 1997;71:9743&#x2013;9752. doi: 10.1128/jvi.71.12.9743-9752.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.71.12.9743-9752.1997</ArticleId><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Liu H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9&#x2013;18. doi: 10.1038/sj.cr.7290105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290105</ArticleId><ArticleId IdType="pubmed">11942415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleschka S. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 2008;389:1273&#x2013;1282. doi: 10.1515/bc.2008.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/bc.2008.145</ArticleId><ArticleId IdType="pubmed">18713014</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 2001;3:301&#x2013;305. doi: 10.1038/35060098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35060098</ArticleId><ArticleId IdType="pubmed">11231581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L.J., Wang W., Liu Y., Ren H., Qi Z.T. Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin. Antivir. Res. 2012;96:260&#x2013;268. doi: 10.1016/j.antiviral.2012.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.09.002</ArticleId><ArticleId IdType="pubmed">22985631</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Yanagawa B., Zhang J., Luo Z., Zhang M., Esfandiarei M., Carthy C., Wilson J.E., Yang D., McManus B.M. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 2002;76:3365&#x2013;3373. doi: 10.1128/jvi.76.7.3365-3373.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.7.3365-3373.2002</ArticleId><ArticleId IdType="pmc">PMC136021</ArticleId><ArticleId IdType="pubmed">11884562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W.R., Chen Y.Y., Yang S.M., Chen Y.L., Horng J.T. Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71. Life Sci. 2005;78:82&#x2013;90. doi: 10.1016/j.lfs.2005.04.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2005.04.076</ArticleId><ArticleId IdType="pmc">PMC7094582</ArticleId><ArticleId IdType="pubmed">16150462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M., Duan H., Gao M., Zhang H., Peng Y. Both ERK1 and ERK2 are required for enterovirus 71 (EV71) efficient replication. Viruses. 2015;7:1344&#x2013;1356. doi: 10.3390/v7031344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7031344</ArticleId><ArticleId IdType="pmc">PMC4379574</ArticleId><ArticleId IdType="pubmed">25803100</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W.H., Hsieh H.L., Lee I.T., Yang C.M. Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma cells: Role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway. J. Cell. Biochem. 2011;112:559&#x2013;570. doi: 10.1002/jcb.22946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.22946</ArticleId><ArticleId IdType="pmc">PMC7166325</ArticleId><ArticleId IdType="pubmed">21268077</ArticleId></ArticleIdList></Reference><Reference><Citation>Law G.L., Tisoncik-Go J., Korth M.J., Katze M.G. Drug repurposing: A better approach for infectious disease drug discovery? Curr. Opin. Immunol. 2013;25:588&#x2013;592. doi: 10.1016/j.coi.2013.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2013.08.004</ArticleId><ArticleId IdType="pmc">PMC4015799</ArticleId><ArticleId IdType="pubmed">24011665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019;18:41&#x2013;58. doi: 10.1038/nrd.2018.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., McKee A.E., Ning Y.M., Hazarika M., Theoret M., Johnson J.R., Xu Q.C., Tang S., Sridhara R., Jiang X., et al. FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin. Cancer Res. 2014;20:4994&#x2013;5000. doi: 10.1158/1078-0432.CCR-14-0776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0776</ArticleId><ArticleId IdType="pubmed">25096067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A., Cohen M.S. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin. Drug Discov. 2016;11:907&#x2013;916. doi: 10.1080/17460441.2016.1201057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2016.1201057</ArticleId><ArticleId IdType="pmc">PMC5443413</ArticleId><ArticleId IdType="pubmed">27327499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W., Yao M., Dong Y., Ye C., Wang D., Liu H., Ma H., Zhang H., Qi L., Yang Y., et al. Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition. Front. Microbiol. 2020;11:1105. doi: 10.3389/fmicb.2020.01105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01105</ArticleId><ArticleId IdType="pmc">PMC7304253</ArticleId><ArticleId IdType="pubmed">32595613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785&#x2013;6797. doi: 10.1074/jbc.RA120.013679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., Smith E.C., Case J.B., Feng J.Y., Jordan R., et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9:e00221-18. doi: 10.1128/mBio.00221-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00221-18</ArticleId><ArticleId IdType="pmc">PMC5844999</ArticleId><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.W., Chik K.K.H., Yuan S.F., Yip C.C.Y., Zhu Z., Tee K.M., Tsang J.O.L., Chan C.C.S., Poon V.K.M., Lu G., et al. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antivir. Res. 2017;141:29&#x2013;37. doi: 10.1016/j.antiviral.2017.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.02.002</ArticleId><ArticleId IdType="pubmed">28185815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., He Y.Q., Yi L.N., Zan H., Kung H.F., He M.L. Viral kinetics of enterovirus 71 in human abdomyosarcoma cells. World J. Gastroenterol. 2011;17:4135&#x2013;4142. doi: 10.3748/wjg.v17.i36.4135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i36.4135</ArticleId><ArticleId IdType="pmc">PMC3203367</ArticleId><ArticleId IdType="pubmed">22039330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Li Z., Huan C., Liu X., Zhang W. SAMHD1 Inhibits Multiple Enteroviruses by Interfering with the Interaction between VP1 and VP2 Proteins. J. Virol. 2021;95:e0062021. doi: 10.1128/JVI.00620-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00620-21</ArticleId><ArticleId IdType="pmc">PMC8316000</ArticleId><ArticleId IdType="pubmed">33883225</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427&#x2013;430. doi: 10.1038/nature08902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08902</ArticleId><ArticleId IdType="pmc">PMC3178447</ArticleId><ArticleId IdType="pubmed">20179705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431&#x2013;435. doi: 10.1038/nature08833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08833</ArticleId><ArticleId IdType="pubmed">20130576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Yao R., Biza S., Zusinaite E., Mannik A., Kivi G., Planken A., Kurg K., Tombak E.M., Ustav M., Jr., et al. Identification and Tracking of Antiviral Drug Combinations. Viruses. 2020;12:1178. doi: 10.3390/v12101178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12101178</ArticleId><ArticleId IdType="pmc">PMC7589631</ArticleId><ArticleId IdType="pubmed">33080984</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzberg M., Boergeling Y., Schrader T., Ludwig S., Ehrhardt C. Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways. Front. Microbiol. 2017;8:2426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735105</ArticleId><ArticleId IdType="pubmed">29312159</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaides T., Nazemi K.J., Crawford J., Kilburn L., Minturn J., Gajjar A., Gauvain K., Leary S., Dhall G., Aboian M., et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002) Oncotarget. 2020;11:1942&#x2013;1952. doi: 10.18632/oncotarget.27600.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.27600</ArticleId><ArticleId IdType="pmc">PMC7260122</ArticleId><ArticleId IdType="pubmed">32523649</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Tilburg C.M., Selt F., Sahm F., Bachli H., Pfister S.M., Witt O., Milde T. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. Pediatr. Blood Cancer. 2018;65:e26893. doi: 10.1002/pbc.26893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.26893</ArticleId><ArticleId IdType="pubmed">29230924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Gao L.Y., Jin Y., Cardona C.J., Xing Z. Regulation of host responses and viral replication by the mitogen-activated protein kinases in intestinal epithelial cells infected with Enterovirus 71. Virus Res. 2015;197:75&#x2013;84. doi: 10.1016/j.virusres.2014.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.12.016</ArticleId><ArticleId IdType="pubmed">25529441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Zhou R., Zhang Z., Jin Y., Cardona C.J., Xing Z. Intrinsic apoptosis and proinflammatory cytokines regulated in human astrocytes infected with enterovirus 71. J. Gen. Virol. 2015;96:3010&#x2013;3022. doi: 10.1099/jgv.0.000235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000235</ArticleId><ArticleId IdType="pubmed">26296773</ArticleId></ArticleIdList></Reference><Reference><Citation>Laajala M., Reshamwala D., Marjomaki V. Therapeutic targets for enterovirus infections. Expert Opin. Ther. Targets. 2020;24:745&#x2013;757. doi: 10.1080/14728222.2020.1784141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1784141</ArticleId><ArticleId IdType="pubmed">32552314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R.Y., Kuo R.L., Ma W.C., Huang H.I., Yu J.S., Yen S.M., Huang C.R., Shih S.R. Heat shock protein-90-beta facilitates enterovirus 71 viral particles assembly. Virology. 2013;443:236&#x2013;247. doi: 10.1016/j.virol.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.05.001</ArticleId><ArticleId IdType="pubmed">23711381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang J.O., Zhou J., Zhao X., Li C., Zou Z., Yin F., Yuan S., Yeung M.L., Chu H., Chan J.F. Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. Biomedicines. 2021;9:88. doi: 10.3390/biomedicines9010088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010088</ArticleId><ArticleId IdType="pmc">PMC7831294</ArticleId><ArticleId IdType="pubmed">33477611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z., Tsang J.O., Yan B., Chik K.K., Chan C.C., Cao J., Liang R., Tang K., Yin F., Ye Z.W., et al. Metabolic Profiling Reveals Significant Perturbations of Intracellular Glucose Homeostasis in Enterovirus-Infected Cells. Metabolites. 2020;10:302. doi: 10.3390/metabo10080302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo10080302</ArticleId><ArticleId IdType="pmc">PMC7466099</ArticleId><ArticleId IdType="pubmed">32717953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Siche S., Moller L., Veit M. Amphipathic Helices of Cellular Proteins Can Replace the Helix in M2 of Influenza A Virus with Only Small Effects on Virus Replication. J. Virol. 2020;94:e01605-19. doi: 10.1128/JVI.01605-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01605-19</ArticleId><ArticleId IdType="pmc">PMC7000973</ArticleId><ArticleId IdType="pubmed">31694941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>